Table of Contents
Overview
Definition of Hepatitis
Hepatitis is defined as inflammation of the liver, which can arise from various causes, including heavy alcohol use, autoimmune disorders, drugs, or toxins. However, the predominant cause of hepatitis is viral infection, commonly referred to as "viral hepatitis".[4.1] This condition can manifest in two primary forms: acute, which is short-lived, and chronic, lasting at least six months. While most cases of acute viral hepatitis resolve independently, some progress to chronic hepatitis.[1.1] In the United States, viral hepatitis represents a significant public health concern, with tens of thousands of new infections occurring annually, leading to thousands of deaths and serving as a leading cause of liver cancer.[2.1] It is estimated that between 3.5 to 5.3 million individuals in the U.S. are living with chronic viral hepatitis, a disease often characterized by a lack of symptoms until severe liver damage has occurred.[3.1] The most common types of viral hepatitis in the United States include hepatitis A, hepatitis B, and hepatitis C.[4.1]Types of Hepatitis
Hepatitis is primarily categorized into three common types: hepatitis A, hepatitis B, and hepatitis C, each differing in transmission, symptoms, treatment, and prevention strategies.[5.1] Hepatitis A is known to cause only acute illness, while both hepatitis B and C can lead to chronic infections.[14.1] Chronic hepatitis B can often remain asymptomatic until significant liver damage occurs, increasing the risk of cirrhosis and liver cancer.[14.1] The pathophysiological differences between acute and chronic hepatitis are significant. Acute hepatitis is characterized by a predominantly lobular injury pattern, while chronic hepatitis typically presents with portal or periportal inflammation and varying degrees of fibrosis.[13.1] In acute hepatitis, the immune response involves T cell-mediated killing of infected hepatocytes, leading to active regeneration of these cells.[11.1] Conversely, chronic hepatitis B virus (HBV) carriers who experience superinfection with hepatitis D virus (HDV) tend to have more severe acute hepatitis and a higher likelihood of developing chronic HDV infection, which can result in fulminant liver failure and cirrhosis.[12.1] Chronic hepatitis B and C infections can lead to severe complications, including chronic active hepatitis, liver failure, cirrhosis, and hepatocellular carcinoma (HCC).[12.1] Specifically, chronic hepatitis B virus (HBV) carriers who experience superinfection with hepatitis D virus (HDV) are at an increased risk of developing more severe acute hepatitis and chronic HDV infection, which can further exacerbate liver damage.[12.1] The introduction of direct-acting antiviral agents (DAAs) has significantly transformed the treatment landscape for chronic hepatitis C, achieving high rates of sustained virological response and improving patient outcomes.[34.1] Recent updates in treatment guidelines have also expanded eligibility for simplified chronic HCV infection treatment, allowing for minimal monitoring in adults.[33.1] These advancements underscore the critical need for early detection and effective management of chronic hepatitis to enhance patient care and prevent severe liver-related complications.[12.1]History
Milestones in Hepatitis Research
The history of hepatitis research is marked by several significant milestones that have shaped our understanding of the disease and its causative agents. The recognition of hepatitis as an infectious disease dates back to the dawn of recorded history; however, the differentiation between hepatitis A (infectious hepatitis) and hepatitis B (serum hepatitis) was not established until the first half of the 20th century.[46.1] A significant milestone in hepatitis research was achieved in 1965 with the discovery of the "Australia antigen," which was later identified as the hepatitis B virus surface antigen (HBsAg). This discovery is often regarded as a critical breakthrough in the long-standing effort to understand the pathogenesis of infectious hepatitis and is seen as marking the beginning of modern hepatitis research.[49.1] The identification of hepatitis B led to the development of the hepatitis B vaccine, recognized as the first vaccine not prepared by tissue.[44.1] Following this, researchers employed similar methodologies to identify the hepatitis A virus, which was ultimately discovered when they shifted their focus from serum to feces and utilized appropriate technology.[50.1] The impact of World War II on hepatitis research cannot be understated. An outbreak of hepatitis related to the yellow fever vaccine prompted a significant research effort to understand the disease better.[47.1] This period also saw the gradual identification of distinct hepatitis agents, culminating in the classification of hepatitis A and B, which revolutionized public health approaches to the disease.[55.1] In the subsequent decades, the discovery of the hepatitis C virus (HCV) marked a significant advancement in the field of hepatitis research. It was established that HCV infection is associated with both acute and chronic hepatitis, as well as liver cancer. Over the next 25 years, researchers faced numerous challenges, including the inability to culture patient viruses in the laboratory. Despite these obstacles, impressive advances were made in understanding HCV's genetic heterogeneity and complex life cycle.[51.1] Technological advancements during this period allowed for the identification of various hepatitis viruses, and subsequent scientific inquiry revolutionized the understanding of the morbidity and mortality caused by these viral pathogens.[54.1] This evolution in the classification and understanding of hepatitis has led to significant medical advancements, including the development of vaccines and antiviral therapies, which have greatly impacted prevention and treatment strategies.[52.1]Recent Advancements
Innovations in Treatment
Significant innovations in the treatment of hepatitis have emerged in recent years, particularly in the management of hepatitis C and hepatitis B. The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment, achieving over 85% sustained virological response rates and offering shorter treatment durations with fewer side effects compared to older therapies.[94.1] These advancements have prompted the World Health Organization to set an ambitious goal for the eradication of hepatitis C by 2030, emphasizing the need for equitable access to these treatments among vulnerable populations.[89.1] The integration of genetic testing has further improved patient outcomes in hepatitis C treatment. Host genetic factors, including variations in the IL28B gene, play a crucial role in determining the efficacy of antiviral therapies, especially for patients undergoing interferon-based treatments.[95.1] Genetic testing can help identify the most effective DAA regimen for individual patients, thereby enhancing the chances of achieving a cure while minimizing potential side effects.[86.1] Furthermore, some single nucleotide polymorphisms have been associated with the clinical presentation and response to antiviral treatment in individuals with chronic hepatitis C, highlighting the importance of understanding genetic influences on treatment outcomes.[96.1] In the treatment of chronic hepatitis B virus (HBV) infection, recent advancements have focused on achieving a "functional cure." Traditional treatment methods often require long-term management; however, novel therapeutic strategies are being explored. These include the use of one or more direct-acting antivirals combined with at least one immunomodulator, representing a promising approach to addressing the viral persistence that poses a significant obstacle to curing chronic hepatitis B.[90.1] Additionally, several therapeutic vaccines, including recombinant pre-S1, pre-S2 vaccines and T-cell peptide vaccines, have been evaluated. These vaccines are noted for their higher immunogenicity compared to existing commercial vaccines, generating stronger HBV-specific B-cell and T-cell responses.[112.1] Despite these advancements, significant challenges remain due to the integration of HBV into the host DNA, complicating treatment efforts.[88.1] Overall, these innovations reflect the ongoing efforts to develop more effective therapeutic strategies for chronic hepatitis B, as highlighted in recent reviews summarizing promising approaches for treatment and prevention.[111.1]In this section:
Epidemiology
Global Prevalence
The global prevalence of hepatitis remains a significant public health concern, with varying trends observed across different types of the virus. Hepatitis A, for instance, has seen a notable increase in incidence, particularly among adults in the United States, Europe, and Asia. This rise is primarily attributed to person-to-person transmission linked to substance use, homelessness, and sexual practices among men who have sex with men.[140.1] In 2022, the Centers for Disease Control and Prevention (CDC) reported 2,265 cases of hepatitis A, which corresponded to an estimated 4,500 infections after adjusting for underreporting.[132.1] Furthermore, as of July 2023, there were 44,896 reported cases of hepatitis A in the U.S., resulting in 27,428 hospitalizations and 423 deaths.[133.1] In contrast, the epidemiology of hepatitis B and C shows a predominantly declining prevalence globally. The implementation of universal hepatitis B vaccination programs has significantly contributed to this decline, although substantial gaps in prevention efforts remain.[139.1] An estimated 2.2 million people in the U.S. are living with hepatitis B, while approximately 2.4 million are affected by hepatitis C.[143.1] The rate of new hepatitis C infections has quadrupled since 2010, particularly among individuals in their 20s and 30s, with injection drug use identified as the primary transmission route.[134.1] Despite ongoing efforts to meet global hepatitis elimination targets by 2030, significant challenges remain. Achieving these targets is projected to save millions of lives and prevent new infections. In the United States, progress has been observed, with the country on track to meet or exceed its 2025 targets for reducing acute hepatitis B infections and increasing the rate of hepatitis B "birth dose" vaccinations, as well as reducing the rate of hepatitis C-related deaths.[131.1] However, despite this progress, the nation is still failing to meet its 2025 targets for reducing hepatitis C-related deaths, indicating that further action is necessary to address these public health challenges.[131.1] The implementation of policies, such as the World Health Organization's recommendation for testing all pregnant women for hepatitis B during their pregnancy, is crucial in the broader strategy to eliminate mother-to-child transmission of hepatitis and other infections.[144.1] These trends underscore the need for comprehensive public health strategies that address the complexities of hepatitis transmission and the social determinants of health that contribute to its spread.Symptoms And Complications
Common Symptoms
The symptoms of hepatitis can vary significantly depending on the type and severity of the condition. Common symptoms include loss of appetite, fatigue, mild fever, muscle or joint aches, nausea and vomiting, and abdominal pain.[186.1] In cases of acute hepatitis B, symptoms typically appear an average of 90 days after exposure and may include dark urine, clay-colored stools, jaundice, and joint pain.[187.1] Chronic hepatitis C patients often experience a range of symptoms, with fatigue and sleep disturbances being the most prevalent. Other less common symptoms may include nausea, diarrhea, abdominal pain, anorexia, myalgia, arthralgia, weakness, and weight loss.[189.1] It is important to note that the presence of symptoms can indicate that chronic liver disease and liver damage are already progressing, which can lead to serious and potentially life-threatening complications.[188.1]Long-term Complications
Long-term complications of hepatitis can vary significantly between acute and chronic forms of the disease. Acute hepatitis generally does not lead to long-term concerns; however, chronic infections, particularly with hepatitis B virus (HBV) and hepatitis C virus (HCV), can result in severe complications. These complications may include cirrhosis, acute and chronic liver disease, and hepatocellular carcinoma, particularly in patients with chronic HBV or HCV infections.[176.1] Chronic HBV carriers who experience superinfection with hepatitis D virus (HDV) are at an increased risk of developing more severe acute hepatitis and chronic HDV infection, which can lead to fulminant liver failure and progression to cirrhosis in a majority of cases.[176.1] Furthermore, chronic hepatitis B is associated with a significant risk of developing chronic active hepatitis, acute or subacute hepatic necrosis, liver failure, and hepatic encephalopathy.[176.1] The distinction between acute and chronic hepatitis is crucial for understanding disease progression and management. Chronic hepatitis B, if left untreated, can lead to serious outcomes such as liver cirrhosis, liver failure, or liver cancer.[208.1] Approximately 15% to 25% of individuals with chronic hepatitis C may develop chronic liver disease, including cirrhosis, over a span of 10 to 20 years.[208.1]Prevention
Vaccination Strategies
Vaccination is a critical strategy in the prevention of hepatitis, particularly hepatitis A and B, which can lead to severe health complications, including liver cancer and chronic liver disease.[214.1] The Centers for Disease Control and Prevention (CDC) emphasizes that the best way to prevent hepatitis B is through vaccination, which is safe and effective. The CDC recommends that almost everyone receive the hepatitis B vaccine, with all infants receiving it shortly after birth.[216.1] Similarly, vaccination is also the most effective method to prevent hepatitis A, especially for high-risk groups such as international travelers, individuals experiencing homelessness, and men who have sex with men.[217.1] The implementation of hepatitis B vaccination programs has significantly decreased the carrier rate and related morbidity and mortality.[230.1] Public health campaigns that provide clear and culturally sensitive information about the risks of hepatitis B and the benefits of vaccination have been shown to empower individuals to make informed health decisions.[231.1] However, barriers to vaccination persist, particularly among at-risk populations, including those with chronic liver disease and individuals who inject drugs. Financial obstacles, such as lack of health insurance and high costs, can hinder vaccine uptake.[232.1] The Affordable Care Act mandates coverage for ACIP-recommended vaccines without copays for private insurance, yet disparities remain for Medicaid recipients, indicating that financial barriers must be addressed comprehensively.[232.1] To enhance vaccination rates, particularly in underserved populations, several innovative strategies have been employed. These include the implementation of standing orders for vaccination, which have proven effective in increasing adult vaccination rates.[233.1] Additionally, health departments have successfully engaged underserved populations by adopting innovative vaccine delivery methods and creating flexible solutions for vaccine tracking.[238.1] Continuous engagement with these communities is essential, requiring sustained commitment and culturally responsive strategies to address their diverse needs.[240.1] The Community Preventive Services Task Force recommends a combination of community-based interventions, such as partnering with local organizations and employing reminder systems, to boost vaccine demand and access.[241.1]Public Health Initiatives
Public health initiatives aimed at preventing hepatitis have increasingly focused on understanding demographic trends and implementing targeted strategies to engage high-risk populations. In the United States, approximately 2.4 million people are estimated to be living with hepatitis C, with a significant portion—51%—unaware of their infection status. The rise in acute hepatitis C infections, which increased by 250% from 2010 to 2014, highlights the urgent need for effective prevention strategies, particularly in areas affected by the opioid epidemic.[218.1] In 2022, the CDC reported 4,848 acute hepatitis C cases, with the highest incidence among individuals aged 30-39 years, indicating that targeted interventions for this demographic are crucial.[219.1] Effective prevention strategies include harm reduction measures and safe injection practices, particularly for people who inject drugs (PWIDs), as these approaches have been shown to reduce transmission rates among high-risk groups.[225.1] Additionally, integrating viral hepatitis prevention and control activities into existing public health programs is essential, especially given the decreasing resources available for public health initiatives.[226.1] This integration can enhance the effectiveness of interventions aimed at improving hepatitis B vaccination and testing among key populations.[227.1] Community engagement plays a vital role in these public health efforts. By fostering collaboration with affected communities, initiatives can reduce stigma, disseminate accurate information, and encourage early diagnosis.[229.1] Culturally tailored health education campaigns are particularly effective in raising awareness about the links between hepatitis B and liver cancer, thereby promoting screening and vaccination in disproportionately impacted groups, such as Asian and Pacific Islander, African, and Caribbean immigrant populations.[247.1] These campaigns must respect social and cultural norms, especially regarding sensitive topics like sexual health, to resonate effectively with the target audience.[248.1]In this section:
Treatment Approaches
Antiviral Therapies
Recent advancements in antiviral therapies for hepatitis B and C have significantly transformed treatment approaches, leading to improved patient outcomes. The introduction of direct-acting antivirals (DAAs) has revolutionized the management of hepatitis C virus (HCV) infection, achieving high response rates exceeding 95% and simplifying treatment protocols, which allows non-specialists to manage patients without advanced liver disease.[268.1] These therapies are characterized by their all-oral regimens, which are better tolerated compared to older interferon-based treatments, thus enhancing patient adherence and overall treatment success.[267.1] In the context of hepatitis B, advancements have also been made through the identification of novel biomarkers that facilitate the development of personalized treatment plans. These biomarkers, such as hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen, help in selecting patients who may benefit from cessation of long-term antiviral therapy.[260.1] Furthermore, the understanding of how hepatitis B virus (HBV) interacts with the host immune system has led to the exploration of new treatment options tailored to individual patient needs.[260.1] The latest antiviral drugs for hepatitis C, including Mavyret, Vosevi, and Epclusa, have received FDA approval for treating various genotypes of HCV, demonstrating efficacy in both patients with and without cirrhosis.[265.1] Additionally, the combination of bemnifosbuvir and ruzasvir shows promise due to its potent, pan-genotypic antiviral activity, indicating a shift towards more effective treatment combinations.[266.1] Long-term benefits of these antiviral therapies extend beyond immediate viral suppression; they include a reduced risk of developing hepatocellular carcinoma and a decreased need for liver transplantation.[279.1] The assessment of treatment effectiveness involves monitoring liver histopathological changes and the occurrence of liver cirrhosis, which are critical indicators of clinical outcomes.[278.1] Current international guidelines emphasize the importance of close monitoring and evaluation, particularly for patients in the indeterminate phase of chronic hepatitis B.[281.1]Management of Chronic Hepatitis
Management of chronic hepatitis, particularly hepatitis B and C, requires a comprehensive approach aimed at reducing liver inflammation and fibrosis while preventing the progression to cirrhosis and its associated complications.[251.1] Antiviral medications have been shown to be effective for both hepatitis B and C.[250.1] Recent advancements in hepatitis C treatment represent significant progress in the field of viral hepatitis, although some challenges remain.[252.1] For chronic hepatitis C virus (HCV) infections, therapies such as the fixed-dose combination of sofosbuvir and ledipasvir, as well as grazoprevir-elbasvir combinations, have been utilized in clinical trials, demonstrating efficacy in both treatment-naive and previously treated patients.[251.1] In contrast, despite recent advances in understanding hepatitis B virus (HBV), significant obstacles persist due to its integration into the host DNA.[252.1] The treatment landscape for hepatitis B virus (HBV) is more complex due to the virus's ability to integrate into the host DNA, which presents significant challenges in achieving complete eradication. While current antiviral therapies can suppress the virus, they do not yet provide a cure. However, promising approaches, including immunomodulatory therapies and gene silencing technologies, are under investigation.[255.1] The management strategies for viral hepatitis are tailored to the specific type and stage of the infection. For instance, hepatitis A can often be prevented through vaccination, while hepatitis C treatment has seen the most significant advancements in recent decades, with a high cure rate of approximately 95% using direct-acting antiviral agents.[272.1] Moreover, the implementation of new guidelines aims to increase access to treatment for hepatitis B, potentially raising the percentage of individuals receiving care from 8-15% to 50% by 2030. This initiative underscores the importance of equitable access to treatment, particularly in high-burden regions.[256.1] Overall, the management of chronic hepatitis requires ongoing research, community engagement, and advocacy to improve treatment outcomes and address health disparities.In this section:
Future Directions
Research and Development
Future directions in hepatitis research and development are focused on several key areas aimed at improving treatment outcomes and ultimately achieving the elimination of viral hepatitis. The World Health Organization (WHO) has set an ambitious target to eliminate viral hepatitis B and C by 2030, emphasizing the importance of vaccination against hepatitis B as a primary strategy for controlling and eliminating Hepatitis B Virus (HBV) infection.[297.1] Recent advancements in hepatitis treatment have significantly improved patient prognoses, with new antiviral medications, effective vaccination programs, and better diagnostic techniques transforming management strategies.[299.1] In particular, the treatment of hepatitis C has seen remarkable progress, marking it as one of the most significant advancements in viral hepatitis over the past decades.[301.1] However, challenges remain, especially in the treatment of hepatitis B, where the virus's integration into host DNA complicates therapeutic approaches.[301.1] Research is also focusing on the development of therapies that target multiple pathways involved in viral pathogenicity and replication, alongside the identification of new biomarkers that could refine the definition of "cure" in hepatitis treatment.[296.1] The therapeutic use of microRNAs (miRNAs) is emerging as a promising avenue for enhancing treatment effectiveness and minimizing side effects, potentially paving the way for personalized medicine in hepatitis care.[302.1] Moreover, precision medicine is anticipated to optimize therapeutic outcomes through targeted therapies tailored to specific molecular pathways and patient characteristics. Direct-acting antivirals are already being utilized to create personalized treatment regimens based on viral genotype and host factors.[305.1] The integration of artificial intelligence and machine learning into hepatitis research is also expected to enhance predictive capabilities based on genetic data, further advancing personalized treatment approaches.[303.1]Goals for Hepatitis Elimination
The World Health Organization (WHO) has established ambitious goals for the elimination of hepatitis B and C as public health threats by 2030. This initiative aims for a 90% reduction in the incidence of hepatitis B virus (HBV) and an 80% reduction for hepatitis C virus (HCV), alongside a 65% reduction in mortality compared to 2015 levels.[322.1] Achieving these targets is crucial, as hepatitis B and C are responsible for chronic diseases affecting hundreds of millions globally, leading to liver cirrhosis, liver cancer, and significant mortality.[321.1] To achieve the goal of eliminating hepatitis as a major public health threat, effective vaccination programs are crucial. Vaccines for hepatitis A, B, and E are currently available and can significantly contribute to prevention efforts.[308.1] It is essential to implement these vaccines across a wide range of clinical and nontraditional community-based settings, including HIV and STI clinics, refugee health clinics, and organizations that serve marginalized populations, such as people who use drugs and those experiencing homelessness.[339.1] Additionally, advancements in treatment for chronic hepatitis C, including new oral regimens, have demonstrated cure rates exceeding 90%, which offers promising prospects for improving patient outcomes.[308.1] Despite the global commitment to eliminate hepatitis B and C, significant challenges persist. An estimated 354 million individuals worldwide are living with chronic hepatitis B or C, with many lacking access to essential testing and treatment services.[321.1] If current trends continue, it is projected that 19 million hepatitis-related deaths could occur between 2015 and 2030.[318.1] To address these challenges, community engagement and advocacy are crucial for improving service delivery and reducing stigma associated with chronic viral hepatitis.[309.1] Community-based organizations play a vital role in connecting patients, providers, and policymakers, which is essential for bridging gaps in achieving the goal of hepatitis elimination by 2030.[310.1] The elimination of hepatitis B and C by 2030 is a critical public health goal, with the potential to prevent nearly 90,000 deaths in the United States alone.[317.1] Currently, these diseases are responsible for over 20,000 deaths annually, highlighting the urgent need for effective public health strategies.[317.1] The Viral Hepatitis National Strategic Plan outlines goal-oriented objectives and strategies that can be implemented by a diverse array of stakeholders across various sectors to reverse the rates of viral hepatitis, prevent new infections, and improve care and treatment.[341.1] This plan includes the implementation of universal hepatitis C screening guidelines, hepatitis B testing, and linkage to care in multiple settings, which are essential for addressing the public health threat posed by these viruses.[341.1] By focusing on these targeted interventions, the goal of eliminating viral hepatitis can be achieved, ultimately enhancing care and treatment for affected populations.[341.1]In this section:
References
[1] Overview of Hepatitis - Overview of Hepatitis - The Merck Manuals — Hepatitis is common throughout the world. Hepatitis can be. Acute (short-lived) Chronic (lasting at least 6 months) Most cases of acute hepatitis caused by a virus (acute viral hepatitis) resolve on their own, but some progress to chronic hepatitis.(See also Overview of Acute Viral Hepatitis and Overview of Chronic Hepatitis.)
[2] Clinical Overview of Viral Hepatitis - CDC — Overview of Viral Hepatitis in the US. Each year, tens of thousands of people acquire a viral hepatitis infection in the United States. It is a serious public health threat that kills thousands of Americans annually and is a leading cause of liver cancer.
[3] Overview of Viral Hepatitis - Addressing Viral Hepatitis in People With ... — An estimated 3.5-5.3 million people in the United States live with chronic viral hepatitis (Institute of Medicine [IOM], 2010). Viral hepatitis is often a silent disease whose symptoms and signs become evident only after the disease has caused severe liver damage. The symptoms of hepatitis can take decades to manifest, so many people who are infected with hepatitis are unaware that they have
[4] Viral Hepatitis - StatPearls - NCBI Bookshelf — Hepatitis is defined as inflammation of the liver that can result from a variety of causes, such as heavy alcohol use, autoimmune disorders, drugs, or toxins. However, the most frequent cause of hepatitis is due to a viral infection, referred to as "viral hepatitis." In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C.
[5] Hepatitis A, B, and C: What to Know About Each Type - Healthline — Learn about the three most common types of viral hepatitis in the United States: hepatitis A, B, and C. Find out how they differ in transmission, symptoms, treatment, and prevention.
[11] Acute hepatitis - PMC — Acute hepatitis develops because of immune recognition of infected liver cells, which results in T cell mediated killing of hepatocytes. Active regeneration of hepatocytes then occurs. As well as a cell mediated immune response, a humoral immune response develops; this is probably important in removing viral particles from the blood and thus
[12] Viral Hepatitis - StatPearls - NCBI Bookshelf — Chronic hepatitis B virus carriers who develop superinfection with HDV tend to have more severe acute hepatitis, and the majority of these patients will develop chronic HDV infection. Chronic infection with both HBV and HDV can lead to fulminant liver failure, severe chronic active hepatitis, and progression to cirrhosis in a majority of patients compared to those patients who only have chronic HBV infection. Patients with HBV infection are at risk of developing chronic hepatitis and cirrhosis, as well as hepatocellular carcinoma as a consequence. Complications of viral hepatitis include chronic infection with chronic active hepatitis, acute or subacute hepatic necrosis, liver failure, cirrhosis, hepatic encephalopathy, and hepatocellular carcinoma in patients with HBV or HCV infection.
[13] Pathology Outlines - Hepatitis (acute and chronic)-general — Acute hepatitis: Predominantly lobular injury pattern Chronic hepatitis: Predominantly portal / periportal inflammation, with varying degrees of fibrosis (World J Gastroenterol 2016;22:1357) Lobular inflammation and necrosis: Necrosis may be spotty, confluent or bridging Apoptotic bodies (acidophilic bodies / Councilman bodies)
[14] Hepatitis A, B, and C: What to Know About Each Type - Healthline — What is hepatitis? Hepatitis A Many people with chronic hepatitis B don’t have symptoms until significant liver damage has occurred. Antiviral medications are available for people with chronic hepatitis B. Having chronic hepatitis B can increase your risk for developing cirrhosis or liver cancer. chronic | acute only | can be acute or chronic; most adults clear the virus, but children who contract HBV are more likely to have chronic hepatitis B | can be acute or chronic; over half of people that contract the virus will develop a chronic hepatitis C Hepatitis A, B, and C are all caused by different viruses. Additionally, hepatitis A only causes an acute illness while hepatitis B and C can become chronic.
[33] Hepatitis C Guidance 2023 Update: American ... - Oxford Academic — Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases- Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection ... expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and
[34] Chronic Hepatitis C: Advances in Therapy and the Remaining ... - PubMed — Hepatitis C virus (HCV) infection contributes significantly to liver cirrhosis and hepatocellular carcinoma (HCC), often requiring liver transplantation. Introducing direct-acting antiviral agents (DAAs) has radically changed HCV treatment. DAAs achieve high rates of sustained virological response ( …
[44] A brief history of hepatitis milestones - Wiley Online Library — The history of the discovery of hepatitis viruses is one of the most fascinating scientific adventures of the last 50 years. Their identification has been associated with unique cognitive milestones and breakthroughs which revolutionized medicine and public health. The discov-ery of HBV started the process by bringing the hepatitis B vaccine, the first ever vaccine not prepared by tissue
[46] Hepatitis - Office of NIH History and Stetten Museum — Hepatitis Human hepatitis has been recognized since the dawn of recorded history, but proof of infectious cause and delineation of hepatitis A (infectious hepatitis) from hepatitis B (serum hepatitis) were not established until the first half of the 20th century.
[47] History of the Discovery of Hepatitis A Virus - PMC - PubMed Central (PMC) — Viral hepatitis was a major problem for both the Allies and the Axis during World War II. Early in the war, an outbreak of hepatitis related to yellow fever vaccine, stabilized with human serum involving 49,233 clinically apparent cases (Seeff et al. 1987), prompted a major hepatitis research effort. As the records on the vaccinees were very
[49] A historical perspective on the discovery and elucidation of the ... — The discovery in 1965 of the "Australia antigen," subsequently identified as the hepatitis B virus surface antigen (HBsAg), was such a watershed event in virology that it is often thought to mark the beginning of hepatitis research, but it is more accurately seen as a critical breakthrough in a long effort to understand the pathogenesis of infectious hepatitis.
[50] History of the Discovery of Hepatitis A Virus - PMC - PubMed Central (PMC) — After the discovery of Australia antigen and its association with hepatitis B, similar methodologies were used to find the hepatitis A virus. The virus was ultimately identified when investigators changed the focus of their search from serum to feces and applied appropriate technology.
[51] The history of hepatitis C virus (HCV): Basic research reveals unique ... — It was established that HCV infection is associated with acute and chronic hepatitis and liver cancer , , .During the next 25 years, despite numerous huge challenges including the inability to culture patient viruses in the laboratory, impressive advances have been made in strives to understand HCV's genetic heterogeneity and complex life cycle, and in developing experimental
[52] Viral Hepatitis: Historical Perspectives from the 20th to the 21st Century — AI-generated Abstract This review provides a comprehensive overview of the historical perspectives on viral hepatitis from the 20th to the 21st century, emphasizing significant medical advancements in understanding the etiology, prevention, and treatment of the disease. It discusses the impact of research accomplishments, such as the development of vaccines and antiviral therapies, on the
[54] From hepatitis A to E: A critical review of viral hepatitis — Technological advancements over the modern era allowed for the viruses to be identified and subsequent scientific inquiry revolutionized the morbidity and mortality caused by these viral pathogens. We aim to provide an overview of viral hepatitis with discussion of current and prospective therapies.
[55] A brief history of hepatitis milestones - Trepo - 2014 - Liver ... — Hepatitis has been a major plague of mankind. The history of the discovery of causative viruses is one of the most fascinating scientific adventures of this half century. Individualization of several types of hepatitis only emerged after world war two. Their identification has been associated with milestones which revolutionized medicine and public health. The discovery of HBV brought the
[86] Advances in Hepatitis Treatment - Fundahigado America — This approach improves the efficacy of treatments and minimizes side effects. For example, in hepatitis C treatment, genetic testing can help determine the most effective DAA regimen for a patient, enhancing the chances of a cure. Conclusion. In summary, the recent advances in hepatitis treatment have significantly improved the prognosis for
[88] A Focused Review on Recent Advances in the Diagnosis and Treatment of ... — Hepatitis C treatment is the biggest advancement of viral hepatitis in the past decades, although minor issue is still present. In contrast, despite the recent advances in understanding HBV, significant obstacles exist due to its integration to the host DNA. The first approved medication in EU for hepatitis D is promising.
[89] Present and future management of viral hepatitis - PMC — The spectacular advances in hepatitis C virus treatment have led the World Health Organization to propose the objective of its eradication by 2030. The key aspect to achieving this goal is to ensure that these treatments reach all the more vulnerable population groups, in whom the different types of viral hepatitis have a high prevalence and
[90] A Focused Review on Recent Advances in the Diagnosis and Treatment of ... — Effective treatment is also available for people with chronic hepatitis B virus infection; although for most people such treatment needs to be long-term, and recent advanced aim at a "functional cure" of hepatitis B. In this review article, we discuss the most recent advances of the diagnosis and treatment of viral hepatitis.
[94] What are Direct-Acting Antivirals (DAAs) for Hepatitis C Treatment? — Direct-acting antivirals (DAAs) are a newer class of drugs used to treat hepatitis C. DAAs target specific steps in the hepatitis C virus (HCV) life cycle. DAAs have shorter treatment times, fewer side effects, and higher SVR rates than older drugs.
[95] The role of genetic markers in hepatitis C virus therapy: a ... - PubMed — It has been understood for some time that the treatment outcome of hepatitis C virus (HCV) infection is influenced by host genetic factors. Three independent genome-wide association studies have recently identified that a genetic variation in the IL28B gene [interferon-λ3 (IFN-λ3)] determines the outcome of IFN-α-based therapy in patients with genotype 1 chronic hepatitis C infection.
[96] Role of genetic polymorphisms in hepatitis C virus chronic infection — Core tip: Some single nucleotide polymorphisms have been associated with the clinical presentation and/or response to antiviral treatment in subjects with chronic hepatitis C (CHC). In this review article the effect of old and new host genetics factors [interleukin 28B, inosine triphosphate pyrophosphatase, patatin-like phospholipase domain, cannabinoid receptor type 2 (CB2-63), vitamin D
[111] Chronic Hepatitis B Infection: New Approaches towards Cure — Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. ... Chronic Hepatitis B Infection: New Approaches towards Cure. Mojisola Ogunnaike. ... This review summarizes the current and emerging promising therapeutic strategies for chronic HBV treatment and prevention . Figure 1. Open in a new tab.
[112] The roadmap towards cure of chronic hepatitis B virus infection — Therapeutic vaccines: Several recombinant pre-S1, pre-S2 vaccines and T-cell peptide vaccines have been evaluated for the treatment of chronic hepatitis B. They are more immunogenic than the two commercial recombinant S vaccines (Engerix, HBvaxPRO) and can generate stronger protective HBV-specific B-cell and T-cell responses in HBV-naïve
[131] PDF — meeting the global hepatitis elimination targets by 2030 will result in 2.85 million lives saved and 9.5 million new infections and 2.1 million cancer cases prevented. The World Hepatitis Alliance has compiled the key facts from the report to help advocates as they fight for change for people living with hepatitis. Key advocacy messages i.
[132] National Profile of Viral Hepatitis | 2022 Hepatitis Surveillance - CDC — Hepatitis A. During 2022, a total of 2,265 hepatitis A cases were reported to CDC by 50 states and the District of Columbia, corresponding to 4,500 estimated infections (95% confidence interval [CI]: 3,200-5,000) after adjusting for case underascertainment and underreporting (see Technical Notes) 8.The reported case count corresponds to a rate of 0.7 cases per 100,000 population, a 59%
[133] PDF — Widespread Outbreaks of Hepatitis A As of July 7, 2023: - 44,896 cases - 27,428 hospitalizations - 423 deaths Although 33 states have declared outbreaks over, many people remain susceptible to hepatitis A virus Source: (1) CDC, National Notifiable Diseases Surveillance System, 2022 and 2023 data are provisional; (2) Outbreaks of hepatitis A across the U.S. | CDC
[134] Data and Trends | HHS.gov — Reported number of acute hepatitis C cases - United States 2000-2014. The rate of new hepatitis C infections reported to CDC in 2018 was four times as high as it was in 2010. 2018 marked a decade of increases in new hepatitis C infections among people in their 20s and 30s, with injection drug use as the primary route of transmission.
[139] Epidemiology of Hepatitis B and C Viruses: A Global Overview — This article reviews the prevalence, disease burden, genotype distribution, and transmission patterns of hepatitis B virus (HBV) and hepatitis C virus in the 6 World Health Organization regions. The global epidemiology of hepatitis B and C demonstrates a predominantly declining prevalence of the diseases. Improvement in the control of hepatitis B has been largely achieved with implementation
[140] Global burden of liver disease: 2023 update - Journal of Hepatology — An increase in the incidence of hepatitis A infection has been observed in adults in the US, Europe, and Asia 69, 70 primarily related to the higher prevalence of person to person transmission in those with substance use issues, homeless individuals, and men who have sex with men. 71 These same risk factors have long been indications for
[143] PDF — An estimated 2.4 million people in the U.S. are living with hepatitis C infection, and up to 2.2 million people could be living with hepatitis B in the U.S. The need for expanded, standardized, ... Released November 2023 Track changes in the epidemic Eliminate the hepatitis C ... 15% produced hepatitis B prevalence estimates.
[144] PDF — policy implementation as part of its Global Hepatitis Reporting in 2023. Policies on hepatitis B testing of women during pregnancy • WHO recommends that all pregnant women be tested for hepatitis B during their pregnancy as part of triple elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B infections (3-4). Among the
[176] Viral Hepatitis - StatPearls - NCBI Bookshelf — Chronic hepatitis B virus carriers who develop superinfection with HDV tend to have more severe acute hepatitis, and the majority of these patients will develop chronic HDV infection. Chronic infection with both HBV and HDV can lead to fulminant liver failure, severe chronic active hepatitis, and progression to cirrhosis in a majority of patients compared to those patients who only have chronic HBV infection. Patients with HBV infection are at risk of developing chronic hepatitis and cirrhosis, as well as hepatocellular carcinoma as a consequence. Complications of viral hepatitis include chronic infection with chronic active hepatitis, acute or subacute hepatic necrosis, liver failure, cirrhosis, hepatic encephalopathy, and hepatocellular carcinoma in patients with HBV or HCV infection.
[186] Hepatitis Symptoms: Fever, Muscle/Joint Pain, Fatigue, and More - WebMD — The most common symptoms of hepatitis are things like: Loss of appetite; Fatigue; Mild fever; Muscle or joint aches; Nausea and vomiting; Pain in your belly; Some people have other issues, such as:
[187] Clinical Signs and Symptoms of Hepatitis B - CDC — Common symptoms. When present, signs and symptoms for acute hepatitis B appear an average of 90 days after exposure, but range from 60-150 days 1 2. Common symptoms of acute hepatitis B are: Abdominal pain, nausea, and/or vomiting. Dark urine or clay-colored stools. Fatigue. Fever. Jaundice. Joint pain. Loss of appetite. Severity of symptoms
[188] Signs and Symptoms of Hepatitis - Verywell Health — The symptoms of hepatitis can be confounding, ranging from mild, short-lived flu-like symptoms (e.g., fever and fatigue) to more classic ones, such as jaundice—or even no symptoms at all. Typically, once the symptoms of hepatitis become obvious, chronic liver disease and liver damage are well underway. Serious liver damage can have dire and even life-threatening complications such as
[189] Different Types of Hepatitis and Their Symptoms - eMediHealth — Patients with chronic hepatitis C tend to have many symptoms, but it is unclear as to how many of those symptoms are actually due to the hepatitis C infection. The most common symptoms include fatigue and sleep disturbances. Less common symptoms include nausea, diarrhea, abdominal pain, anorexia, myalgia, arthralgia, weakness, and weight loss.
[208] PDF — lasting liver damage; acute illness is rarely fatal • 15%-25% of people with chronic infection develop chronic liver disease, including . cirrhosis, liver failure, or liver cancer • pproximately 5%-25% of persons A with chronic hepatitis C will develop cirrhosis over 10-20 years • eople with hepatitis C and P cirrhosis have a 1%-4
[214] Hepatitis B prevention: Vaccination and other tips - Medical News Today — Preventing hepatitis B is crucial as it has the potential to cause liver cancer and chronic liver disease. Understanding and following prevention strategies, such as vaccination, can significantly
[216] Hepatitis B Prevention and Control | Hepatitis B | CDC — Hepatitis B View All Hepatitis B Hepatitis B Prevention and Control The best way to prevent hepatitis B is by getting vaccinated. CDC estimates that approximately 640,000 people in the United States have chronic, or long-term, hepatitis B. While anyone can get hepatitis B, some people are at a higher risk. Sex partners of people who have hepatitis B. People who live with someone who has hepatitis B. The best way to prevent hepatitis B is by getting vaccinated. Hepatitis B vaccine is safe and effective, and CDC recommends it for almost everyone. All babies will get hepatitis B vaccine shortly after birth. CDC recommends that everyone who is eligible receive hepatitis B vaccination to protect themselves. Hepatitis B Vaccine: Protect Your Baby for Life Hepatitis B
[217] Hepatitis A Prevention and Control | Hepatitis A | CDC — Hepatitis A is a highly contagious virus that spreads through person-to-person contact or consuming contaminated food or drink. Certain groups are at increased risk for infection, including international travelers, people experiencing homelessness, people who use drugs, and men who have sex with men. Vaccination is the best way to prevent hepatitis A.
[218] Data and Trends | HHS.gov — About HHS 2.4 million people are estimated to be living with hepatitis C in the United States. 51% of persons living with hepatitis C infection do not know they have the virus. Hepatitis C infections are increasing in the United States. Acute hepatitis C infections increased 250% from 2010 to 2014. Acute hepatitis C infections increased 364% from 2006 to 2012 in four states affected by the opioid epidemic (Kentucky, Tennessee, Virginia, and West Virginia). Increases in hepatitis B infections are being fueled by the opioid and heroin use epidemics that are gripping many communities across the United States. Hepatitis B and C are responsible for increasing rates of liver cancer and premature deaths. For more information on HHS's web notification policies, see Website Disclaimers.
[219] National Profile of Viral Hepatitis | 2022 Hepatitis Surveillance | CDC — A total of 4,848 acute hepatitis C cases were reported to CDC in 2022 from 46 states and the District of Columbia, corresponding to 67,400 estimated infections (95% CI: 53,300–229,800) after adjusting for case underascertainment and underreporting (see Technical Notes).8 The acute hepatitis C case count corresponds to a reported rate of 1.5 cases per 100,000 population, a 6% decrease from the reported rate during 2021 (1.6 per 100,000 population). Approximately 70% of acute hepatitis C cases reported to CDC during 2022 were among persons aged 20–49 years, with the highest rate among persons aged 30–39 years (3.6 cases per 100,000 population).
[225] Hepatitis C Elimination: Opportunities and Challenges in 2023 — First, intervention is needed to prevent hepatitis C. Effective prevention strategies can be implemented through harm reduction measures, and safe injection practices reduce the transmission of hepatitis C among high-risk populations, such as people who inject drugs (PWIDs).
[226] Integrating Viral Hepatitis Prevention into Public Health Programs ... — Integration is good public health Integrating viral hepatitis prevention and control activities into existing public health programs serving people at high risk for infection makes good public health sense, especially with decreasing resources for public health programs and services.
[227] CDC Collaborates Worldwide to Eliminate Viral Hepatitis — Implement interventions to improve hepatitis B vaccination among key populations and persons at risk of infection. Implement interventions to improve hepatitis B and hepatitis C prevention, testing, and treatment among key populations. Strengthen laboratory capacity to improve diagnostic capacity for viral hepatitis in countries CDC supports.
[229] Expanding community engagement and advocacy in chronic viral hepatitis ... — Community engagement and advocacy are important to drive development and improvement of service delivery for chronic viral hepatitis. Community engagement is defined as the process of working collaboratively with groups of people affiliated by proximity, interests, or situations to support their wellbeing.1 Appropriate community engagement can help to reduce stigma, disseminate messages, and
[230] Hepatitis B Vaccines | The Journal of Infectious Diseases | Oxford Academic — The effective implementation of hepatitis B vaccination programs has resulted in a substantial decrease in the HBV carrier rate and hepatitis B-related morbidity and mortality. This article summarizes the great triumphs of the hepatitis B vaccine, the first anticancer and virus-like-particle-based vaccine.
[231] Hepatitis B and Public Health: Implementing Effective Vaccination Programs — Public health campaigns that provide clear, accurate information about the risks of Hepatitis B and the benefits of vaccination can empower individuals to make informed decisions about their health. These campaigns should be culturally sensitive and tailored to resonate with the specific concerns and values of the target populations.
[232] Vaccine uptake and barriers to vaccination among at-risk adult ... — However, there were limited data reporting on barriers to vaccination among several at-risk populations, including individuals with CLD, ESRD, and IDUs. Studies have demonstrated that a lack of health insurance coverage and high costs can be an obstacle to vaccination, resulting in a high burden of VPDs among at-risk populations.68,72,77 There is evidence that vaccine uptake increases when cost is removed as a barrier; therefore, it is important that there is support from State or Federal policymakers to remove these financial barriers.15,136,137 The Affordable Care Act (ACA) mandates that ACIP-recommended vaccines are covered by private insurance plans without a copay, therefore reducing the financial barrier to insured at-risk adults receiving vaccines.138 However, the ACA does not require State Medicaid agencies to cover all ACIP recommended vaccines for individuals on Medicaid, resulting in a disparity of coverage compared to individuals with private insurance.138 This implies that the cost of vaccination may not be the main barrier to vaccination; however, vaccination cost barriers need to be considered in the context of the potential lack of private insurance among at-risk individuals and a reliance on Medicaid coverage.15,136–138
[233] Preventing Hepatitis B in US Adults Through Vaccination — Implement standing orders, which are among the most effective strategies to improve vaccination rates in adults. 65-68 Sample standing orders, including for hepatitis B vaccination in adults, ... Raising awareness about the burden of hepatitis B in US adults and the link to cirrhosis, liver failure, and liver cancer is an important first step
[238] Strategies for Successful Vaccination Among Two Medically Underserved ... — By engaging medically underserved populations, adopting innovative vaccine delivery methods, and creating flexible solutions to vaccine tracking, health departments have been able to reduce barriers and improve hepatitis A vaccine uptake. Two strategies were consistently successful across health departments during the hepatitis A outbreaks.
[240] Bridging the Gap: Engaging Underserved Populations in Vaccine Access ... — Engaging underserved populations in vaccine access efforts is not a onetime endeavor but a continuous process that requires sustained commitment, collaboration and innovation. By implementing inclusive, culturally responsive strategies that address the diverse needs and barriers faced by underserved communities, we can overcome disparities in
[241] Vaccination Programs: Community-Based Interventions ... - Health — The Community Preventive Services Task Force recommends using a combination of community-based interventions to increase vaccination rates in specific populations. These interventions involve partnering with community organizations, local governments, and vaccine providers to increase community demand for vaccines — like through reminder and recall systems — and increase access to vaccine
[247] The role of culturally appropriate interpersonal communication ... — Introduction: Asian and Pacific Islander (API), African, and Caribbean immigrant groups in the U.S. are disproportionately impacted by chronic hepatitis B and hepatocellular carcinoma (primary liver cancer). Creating educational communication campaigns about hepatitis B and liver cancer for these communities is necessary to increase disease-related awareness and prompt health-promoting behaviors.
[248] The role of culturally appropriate interpersonal communication ... — Community members discussed the need for respect for social and cultural norms within campaign communications specifically about sexual health, given that this is one possible transmission route for hepatitis B. ... and McMenamin, J. Long term outcome of a community-based hepatitis B awareness campaign: eight-year follow-up on linkage to care
[250] WebMD Hepatitis Guide: Treatment — Antiviral medication is effective for hepatitis B and C. Hepatitis A may be prevented with a vaccination, and it requires little treatment in the case of infection. In severe hepatitis cases, a
[251] Viral Hepatitis Treatment & Management - Medscape — For chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections in particular, the goals of therapy are to reduce liver inflammation and fibrosis and to prevent progression to cirrhosis and its complications. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
[252] A Focused Review on Recent Advances in the Diagnosis and Treatment of ... — Hepatitis C treatment is the biggest advancement of viral hepatitis in the past decades, although minor issue is still present. In contrast, despite the recent advances in understanding HBV, significant obstacles exist due to its integration to the host DNA. The first approved medication in EU for hepatitis D is promising.
[255] Update on the management and treatment of viral hepatitis — Update on the management and treatment of viral hepatitis - PubMed Keywords included hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus, hepatitis D virus (HDV), hepatitis E virus, and treatment. Drugs that cure hepatitis B, going beyond viral suppression, are so far unavailable; however, targeted antiviral drugs against HBV (immunomodulatory therapies and gene silencing technologies) are promising approaches to eradicating the virus. Keywords: Hepatitis A virus; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; Hepatitis E virus; Viral hepatitis. Diagrammatic summary of the therapeutic options targeting covalently closed circular deoxyribonucleic acid to prevent hepatitis B virus persistence. cccDNA: covalently closed circular deoxyribonucleic acid; HBV: Hepatitis B virus; RNA: Ribonucleic acid. Hepatitis B virus
[256] Time for a treat all approach for hepatitis B - The Lancet ... — Implementation of the new guidelines will result the number of people living with hepatitis B who can access treatment increasing from 8-15% to 50%—an important step towards achieving elimination of viral hepatitis by 2030. 3 However, if elimination is to be reached, priority must be given to equitable access to treatment for hepatitis B globally, and especially in high-burden regions.
[260] Advances in determining new treatments for hepatitis B infection by ... — Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers - PubMed Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers An improved understanding of how hepatitis B virus (HBV) interacts with the host immune system allows the discovery of novel biomarkers and new treatment options. Viral biomarkers including hepatitis B surface antigen (HBsAg) and newer ones like HBV RNA and hepatitis B core-related antigen appear to be useful to select patients who are likely to benefit from cessation of long-term antiviral therapy. Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
[265] What are the new drugs for the treatment of hepatitis C? — The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir). Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). Mavyret is also approved for patients 3 years and older with HCV genotype 1 infection, who have previously been treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both. Epclusa is also approved in adults and children 3 years of age and older for the treatment of HCV genotype 1, 2, 3, 4, 5 or 6 in patients with decompensated cirrhosis (for use in combination with ribavirin).
[266] Atea Pharmaceuticals Presents Promising Bemnifosbuvir and ... - Nasdaq — The combination of bemnifosbuvir and ruzasvir has the potential to be a promising treatment option for HCV infection, given the potent, pan-genotypic antiviral activity of bemnifosbuvir and
[267] Pangenotypic direct acting antivirals for the treatment of chronic ... — Research in context. Evidence before this study. All-oral, direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection are associated with higher rates of virological cure (sustained virological response) and are better tolerated than older, interferon-based antiviral therapies.
[268] Direct-acting antiviral therapies for hepatitis C infection: global ... — Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV treatment, permitting non-specialists to manage patients without advanced liver disease. We collected and reviewed global data on the registration and reimbursement (government subsidised) of HCV therapies, including restrictions on reimbursement
[272] Connected by Hepatitis C: 5 Individuals Share Their Stories — According to the World Health Organization (WHO), about 30% of those who contract the hep C virus recover from it without any treatment, but the rest go on to develop chronic hepatitis C viral infection. A chronic infection can lead to serious complications such as cirrhosis and liver cancer. About 95% of people treated with direct-acting antiviral agents are cured of hepatitis C infection.
[278] [Current status and future views of indicators for clinical outcome of ... — The optimal clinical outcomes are the original intention and base to form the short-term, long-term and special goals of antiviral treatment in patients with hepatitis B virus (HBV) infection. The immediate indicators for assessment of antiviral clinical outcomes, which usually need prolonged follow-up, include the liver histopathological changes, the occurrence and severity of liver cirrhosis
[279] Impact of modern antiviral therapy of chronic hepatitis B and C on ... — Longer term benefits of antiviral therapy include a reduced risk of developing hepatocellular carcinoma and decreased number of patients requiring liver transplantation. This review article assesses the literature and summarises the impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes from liver disease.
[281] Histological severity, clinical outcomes and impact of antiviral ... — Current international guidelines recommend close monitoring and evaluation of patients with chronic hepatitis B (CHB) in the indeterminate phase, and treatment of patients at high risk of adverse outcomes. Clinical outcomes and the effect of antiviral therapy on the indeterminate phase remain unclear.
[296] Chronic Viral Hepatitis: Current Management and Future Directions — Future directions include a refined definition of "cure," new biomarkers, and development of therapies targeting multiple pathways in the viral pathogenic and replication pathway. Progress is additionally being made on the management of hepatitis D infection. ... Draft update summary: hepatitis C virus infection in adolescents and adults
[297] Advancing hepatitis B elimination: A systematic review of global ... — The World Health Organization (WHO) has set a target of eliminating viral hepatitis B and C by 2030. Vaccination against hepatitis B (HepB) remains the most effective strategy for controlling and eliminating Hepatitis B Virus (HBV) infection. ... A systematic review of global immunization progress and future directions Diagn Microbiol Infect
[299] Advances in Hepatitis Treatment - Fundahigado America — In summary, the recent advances in hepatitis treatment have significantly improved the prognosis for patients. New antiviral medications, effective vaccination programs, better diagnostic techniques, and personalized medicine are transforming the way hepatitis is managed. These innovations offer hope for a future where hepatitis is no longer a
[301] A Focused Review on Recent Advances in the Diagnosis and Treatment of ... — Hepatitis C treatment is the biggest advancement of viral hepatitis in the past decades, although minor issue is still present. In contrast, despite the recent advances in understanding HBV, significant obstacles exist due to its integration to the host DNA. The first approved medication in EU for hepatitis D is promising.
[302] Potential role of microRNAs in personalized medicine against hepatitis ... — The therapeutic use of miRNAs holds promise for enhancing the effectiveness of treatment, reducing side effects, and improving patient well-being . miRNAs could therefore become a valuable tool for personalized medicine in the future. The use of miRNAs in precision medicine is currently in its early stage, and further research is essential to
[303] Tailored Treatments: The Future of Medicine Is Personalized — The future of personalized medicine is incredibly promising, with ongoing research and technological advancements pushing the boundaries of what is possible. Innovations in artificial intelligence (AI) and machine learning are enabling more accurate predictions based on genetic data, while biotechnology is improving the development of
[305] Precision Medicine in Hepatology Personalized Approaches to Liver ... — Precision medicine holds promise for optimizing therapeutic outcomes in liver disease through targeted therapies tailored to specific molecular pathways and patient characteristics. In viral hepatitis, direct-acting antivirals offer personalized treatment regimens based on viral genotype, resistance mutations, and host factors.
[308] A Focused Review on Recent Advances in the Diagnosis and Treatment of ... — Ending hepatitis epidemics as a major public health threat is feasible with the tools and approaches currently available. Effective vaccines are available for preventing viral hepatitis A, B and E infections. New oral, well-tolerated treatment regimens for chronic hepatitis C patients can achieve cure rates of over 90%.
[309] Expanding community engagement and advocacy in chronic viral hepatitis — Community engagement and advocacy are important to drive development and improvement of service delivery for chronic viral hepatitis. Community engagement is defined as the process of working collaboratively with groups of people affiliated by proximity, interests, or situations to support their wellbeing.1 Appropriate community engagement can help to reduce stigma, disseminate messages, and
[310] PDF — a link between patients, providers, and policy makers to bridge gaps in the goal of achieving hepatitis elimination by 2030. Community-based organisations have an essential role in helping providers reach hidden or neglected subpopulations, provide holistic care, and sustain hepatitis care for improved clinical outcomes.
[317] New Report Lays Plan to Eliminate 90,000 Hepatitis B and C Deaths by 2030 — WASHINGTON - Hepatitis B and C kill more than 20,000 people every year in the United States. A new report from the National Academies of Sciences, Engineering, and Medicine presents a strategy to eliminate these diseases as serious public health problems and prevent nearly 90,000 deaths by 2030. "Viral hepatitis is simply not a sufficient priority in the United States," said Brian Strom
[318] Combating hepatitis B and C to reach elimination by 2030 — In the absence of additional efforts, 19 million hepatitis-related deaths are anticipated from 2015 to 2030. Treatment now can prevent deaths in the short- and medium term. The 2014 World Health Assembly requested the World Health Organization to examine the feasibility of eliminating hepatitis B and C, and the 2015 Agenda for Sustainable
[321] Elimination of hepatitis by 2030 - World Health Organization (WHO) — In particular, types B and C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach.
[322] New WHO guidance for country validation of viral hepatitis B and C ... — The 2016 WHO Global Health Sector Strategy (GHSS) on viral hepatitis provided a roadmap for the elimination of viral hepatitis as a public health problem by 2030.1 Elimination is defined as a 90% reduction in incidence (95% for hepatitis B virus [HBV] and 80% for hepatitis C virus [HCV] infection) and a 65% reduction in mortality by 2030, compared with a 2015 baseline, that can be achieved
[339] PDF — Strategies: 1.2.1 Provide viral hepatitis vaccination at a broad range of clinical and nontraditional community-based settings including HIV, STI, refugee health clinics, organizations that serve people who use drugs and/or people experiencing homelessness, and correctional facilities.
[341] Viral Hepatitis National Strategic Plan Overview - HHS.gov — Viral Hepatitis National Strategic Plan Overview | HHS.gov Viral Hepatitis National Strategic Plan Overview The Plan provides goal-oriented objectives and strategies that can be implemented by a broad mix of stakeholders at all levels and across many sectors, both public and private, to reverse the rates of viral hepatitis, prevent new infections, improve care and treatment and ultimately eliminate viral hepatitis as a public health threat in the United States. Seeks to implement universal hepatitis C screening guidelines, hepatitis B testing, and linkage to care in a range of settings and expand the capacity of the public health and provider workforce to provide viral hepatitis prevention, testing, care and treatment services Subscribe to email updates for the latest information about viral hepatitis.